Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Pregnancy Risk Assessment Monitoring System (PRAMS), DP11-001 Panels A, B, and C, Initial Review, 5379-5380 [2011-1998]

Download as PDF Federal Register / Vol. 76, No. 20 / Monday, January 31, 2011 / Notices Dated: January 24, 2011. Carol E. Walker, Acting Reports Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. 2011–2000 Filed 1–28–11; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention jlentini on DSKJ8SOYB1PROD with NOTICES Clinical Laboratory Improvement Advisory Committee (CLIAC) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee: Times and Dates: 9:15 a.m.–5 p.m., March 2, 2011 8:30 a.m.–12:30 p.m., March 3, 2011 Place: CDC, 1600 Clifton Road, NE., Tom Harkin Global Communications Center, Building 19, Room 232, Auditorium B, Atlanta, Georgia 30333. Online Registration Required: In order to expedite the security clearance process at the CDC Roybal Campus located on Clifton Road, all CLIAC attendees are required to register for the meeting online at least 14 days in advance at https://wwwn.cdc.gov/cliac/ default.aspx by clicking the ‘‘Register for a Meeting’’ link and completing all forms according to the instructions given. Please complete all the required fields before submitting your registration and submit no later than February 16, 2011. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people. Purpose: This Committee is charged with providing scientific and technical advice and guidance to the Secretary, Department of Health and Human Services; the Assistant Secretary for Health; the Director, CDC; the Commissioner, Food and Drug Administration (FDA); and the Administrator, Centers for Medicare and Medicaid Services (CMS), regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact on medical and laboratory practice of proposed revisions to the standards; and the modification of the standards to accommodate technological advances. Matters To Be Discussed: The agenda will include agency updates from CDC, CMS, and FDA; presentations and discussions addressing activities of the VerDate Mar<15>2010 16:38 Jan 28, 2011 Jkt 223001 Coordinating Council on the Clinical Laboratory Workforce; the National Institutes of Health Genetic Test Registry design and responses from testing laboratories; current testing practices and oversight of cytogenetic and cytogenomic testing; ongoing studies evaluating laboratory practices; and strategies for developing evidencebased methods for laboratory medicine quality improvement. Agenda items are subject to change as priorities dictate. Providing Oral or Written Comments: It is the policy of CLIAC to accept written public comments and provide a brief period for oral public comments whenever possible. Oral Comments: In general, each individual or group requesting to make an oral presentation will be limited to a total time of five minutes (unless otherwise indicated). Speakers must also submit their comments in writing for inclusion in the meeting’s Summary Report. To assure adequate time is scheduled for public comments, individuals or groups planning to make an oral presentation should, when possible, notify the contact person below at least one week prior to the meeting date. Written Comments: CLIAC accepts written comments until the date of the meeting (unless otherwise stated) for individuals or groups unable to attend the meeting. However, the comments should be received at least one week prior to the meeting date so that the comments may be made available to the Committee for their consideration and public distribution. Written comments and one hard copy with original signature should be provided to the contact person below. In addition, written comments will be included in the meeting’s Summary Report. Contact Person for Additional Information: Nancy Anderson, Chief, Laboratory Practice Standards Branch, Division of Laboratory Science and Standards, Laboratory Science, Policy and Practice Program Office (LSPPPO), Office of Surveillance, Epidemiology and Laboratory Services, CDC, 1600 Clifton Road, NE., Mailstop F–11, Atlanta, Georgia 30333; telephone (404) 498–2741; fax (404) 498–2219; or via email at Nancy.Anderson@cdc.hhs.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 5379 Dated: January 25, 2011. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2011–1999 Filed 1–28–11; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Pregnancy Risk Assessment Monitoring System (PRAMS), DP11–001 Panels A, B, and C, Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Times and Dates: 7:30 p.m.–9 p.m., March 1, 2011 (Closed) 8:30 a.m.–7 p.m., March 2, 2011 (Closed) 8:30 a.m.–5 p.m., March 3, 2011 (Closed) Place: Georgian Terrace Hotel, 659 Peachtree Street, NE., Atlanta, GA 30308, Telephone: (404) 898–8305. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of ‘‘Pregnancy Risk Assessment Monitoring System (PRAMS), DP11–001 Panels A, B, and C.’’ Contact Person for More Information: Donald Blackman, Ph.D., Scientific Review Officer, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office of the Director, Extramural Research Program Office, 4770 Buford Highway, NE., Mailstop K– 92, Atlanta, GA 30341, Telephone: (770) 488–3023, E-mail: DBY7@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. E:\FR\FM\31JAN1.SGM 31JAN1 5380 Federal Register / Vol. 76, No. 20 / Monday, January 31, 2011 / Notices Dated: January 25, 2011. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2011–1998 Filed 1–28–11; 8:45 am] BILLING CODE 4163–18–P Dated: January 26, 2011. Jill Hartzler Warner, Acting Associate Commissioner for Special Medical Programs. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2011–1992 Filed 1–28–11; 8:45 am] Food and Drug Administration BILLING CODE 4160–01–P [Docket No. FDA 2011–N–0002] Advisory Committees; Filing of Closed Meeting Reports AGENCY: Food and Drug Administration, HHS. ACTION: The Food and Drug Administration (FDA) is announcing that, as required by the Federal Advisory Committee Act, the Agency has filed with the Library of Congress the annual reports of those FDA advisory committees that held closed meetings during fiscal year 2010. ADDRESSES: Copies are available from the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, 301–827– 6860. SUMMARY: jlentini on DSKJ8SOYB1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Teresa L. Hays, Committee Management Officer, Advisory Committee and Oversight Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 5290, Silver Spring, MD 20993–0002, 301– 796–8220. SUPPLEMENTARY INFORMATION: Under section 10(d) of the Federal Advisory Committee Act (5 U.S.C. app.1) and 21 CFR 14.60(d), FDA has filed with the Library of Congress the annual reports for the following FDA advisory committees that held closed meetings during the period October 1, 2009, through September 30, 2010: Center for Biologics Evaluation and Research: Blood Products Advisory Committee, Vaccines and Related Biological Products Advisory Committee. National Center for Toxicological Research: Science Board to the National Center for Toxicological Research. Annual reports are available for public inspections between 9 a.m. and 4 p.m., Monday through Friday at the following locations: 1. The Library of Congress, Madison Bldg., Newspaper and Current 16:38 Jan 28, 2011 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2010–N–0567] Notice. VerDate Mar<15>2010 Periodical Reading Room, 101 Independence Ave., SE., rm. 133, Washington, DC; and 2. The Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Jkt 223001 Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Restaurant Menu and Vending Machine Labeling: Recordkeeping and Mandatory Third Party Disclosure Under Section 4205 of the Patient Protection and Affordable Care Act of 2010 AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by March 2, 2011. SUMMARY: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–7285, or e-mailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0665. Also include the FDA docket number found in brackets in the heading of this document. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50– 400B, Rockville, MD 20850, 301–796– 3793. In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed SUPPLEMENTARY INFORMATION: PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 collection of information to OMB for review and clearance. Restaurant Menu and Vending Machine Labeling: Recordkeeping and Mandatory Third Party Disclosure Under Section 4205 of the Patient Protection and Affordable Care Act of 2010—(OMB Control Number 0910– 0665)—Revision On March 23, 2010, the President signed into law the Patient Protection and Affordable Care Act of 2010 (‘‘Affordable Care Act’’) (Pub. L. 111– 148). Section 4205 of the legislation, which principally amends sections 403 and 403A of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 343 and 343–1), requires chain restaurants and similar retail food establishments (SRFE) with 20 or more locations doing business under the same name and offering for sale substantially the same menu items (hereinafter ‘‘chain retail food establishments’’), as well as operators of 20 or more vending machines (hereinafter ‘‘chain vending machine operators’’), to disclose certain nutrition information for certain food items offered for sale so that consumers can make more informed choices about the food they purchase. Section 4205 of the Affordable Care Act preempts State and local governments from establishing menu labeling requirements for chain retail food establishments and vending machine nutrition labeling requirements that are not ‘‘identical to’’ the section 4205 requirements. Section 4205 became effective on the date the law was signed, March 23, 2010. The provisions that went into immediate effect are as follows: For chain retail food establishments: • Disclosing the number of calories in each standard menu item on menus and menu boards, • Making additional written nutrition information available to consumers upon request, • Providing a statement on menus and menu boards about the availability of the written nutrition information, and • Providing calorie information (per serving or per food item) for self-service items and food on display, in a sign adjacent to each food item. For chain vending machine operators: • Providing a sign in close proximity to each article of food (or the selection button) that discloses the number of calories contained in the article, unless a prospective purchaser is able to examine the Nutrition Facts Panel before purchasing the article, or visible nutrition information is otherwise provided at the point of purchase. E:\FR\FM\31JAN1.SGM 31JAN1

Agencies

[Federal Register Volume 76, Number 20 (Monday, January 31, 2011)]
[Notices]
[Pages 5379-5380]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-1998]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Pregnancy Risk Assessment Monitoring System 
(PRAMS), DP11-001 Panels A, B, and C, Initial Review

    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting:

Times and Dates:
    7:30 p.m.-9 p.m., March 1, 2011 (Closed)
    8:30 a.m.-7 p.m., March 2, 2011 (Closed)
    8:30 a.m.-5 p.m., March 3, 2011 (Closed)

    Place: Georgian Terrace Hotel, 659 Peachtree Street, NE., Atlanta, 
GA 30308, Telephone: (404) 898-8305.
    Status: The meeting will be closed to the public in accordance with 
provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and 
the Determination of the Director, Management Analysis and Services 
Office, CDC, pursuant to Public Law 92-463.
    Matters To Be Discussed: The meeting will include the initial 
review, discussion, and evaluation of ``Pregnancy Risk Assessment 
Monitoring System (PRAMS), DP11-001 Panels A, B, and C.''
    Contact Person for More Information: Donald Blackman, Ph.D., 
Scientific Review Officer, CDC, National Center for Chronic Disease 
Prevention and Health Promotion, Office of the Director, Extramural 
Research Program Office, 4770 Buford Highway, NE., Mailstop K-92, 
Atlanta, GA 30341, Telephone: (770) 488-3023, E-mail: DBY7@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.


[[Page 5380]]


    Dated: January 25, 2011.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2011-1998 Filed 1-28-11; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.